Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Melanoma 2Small Cell Lung Carcinoma 1Skin Neoplasms 1Sarcoma 1Neoplasms 1Mesothelioma, Malignant 1Mesothelioma 1

Interventions

Doxorubicin 33Ifosfamide 23Gemcitabine 19pazopanib 18Cyclophosphamide 16Radiotherapy 15pembrolizumab 13Filgrastim 12Docetaxel 12Bevacizumab 10Vincristine 9Sirolimus 9Irinotecan 9Etoposide 9olaratumab 7eribulin 7Sorafenib 7Radiation 7temsirolimus 6Temozolomide 6Mesna 6Magnetic Resonance Spectroscopy 6Cisplatin 6tazemetostat 5cixutumumab 5Trabectedin 5Radiosurgery 5Nivolumab 5Ipilimumab 5Granulocyte Colony-Stimulating Factor 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Sarcoma × ADI PEG20 × Clear all
NCT03449901 2025-12-11

ADI-PEG 20 in Combination With Gemcitabine and Docetaxel for the Treatment of Soft Tissue Sarcoma, Osteosarcoma, Ewing's Sarcoma, and Small Cell Lung Cancer

Washington University School of Medicine

Phase 2 Completed
98 enrolled 12 charts
Sarcoma

Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡